Limb Girdle Muscular Dystrophy clinical trials

Explore recruiting limb girdle muscular dystrophy clinical trials.

Recruiting limb girdle muscular dystrophy studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Limb Girdle Muscular Dystrophy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1-2 multicenter study to evaluate the safety and tolerability of intravenous ATA-100, adeno-associated viral vector carrying the FKRP gene, in patients with FKRP-related limb-girdle muscular dystrophy (LGMDR9, formerly LGMD2I)

Denmark, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effect of EDG-5506 on Biomarker Response to Exercise in Adults with Becker Muscular Dystrophy, McArdle Disease, or Limb-Girdle Muscular Dystrophy

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

Germany, Denmark, Netherlands, Italy, Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I/II, open-label, dose escalation study to evaluate the safety of 2 doses of intravenous ATA-200, an adeno-associated viral vector carrying the human gamma-sarcoglycan gene, in patients with gamma-sarcoglycanopathy (limb-girdle muscular dystrophy LGMDR5, formerly LGMD2C).

France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (ribitol) in Patients with Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Denmark, Italy, Netherlands, Norway, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects with Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)

Spain, Germany, Belgium, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Limb Girdle Muscular Dystrophy trials by city

Limb Girdle Muscular Dystrophy clinical trials

Recruiting limb girdle muscular dystrophy studies right now

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Telecare Psychosocial and Cognitive Intervention for Children and Adolescents With Limb-Girdle Muscular Dystrophy

Also recruiting in Europe

A Phase 1-2 multicenter study to evaluate the safety and tolerability of intravenous ATA-100, adeno-associated viral vector carrying the FKRP gene, in patients with FKRP-related limb-girdle muscular dystrophy (LGMDR9, formerly LGMD2I)

A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effect of EDG-5506 on Biomarker Response to Exercise in Adults with Becker Muscular Dystrophy, McArdle Disease, or Limb-Girdle Muscular Dystrophy

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

A Phase I/II, open-label, dose escalation study to evaluate the safety of 2 doses of intravenous ATA-200, an adeno-associated viral vector carrying the human gamma-sarcoglycan gene, in patients with gamma-sarcoglycanopathy (limb-girdle muscular dystrophy LGMDR5, formerly LGMD2C).

A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (ribitol) in Patients with Limb Girdle Muscular Dystrophy 2I (LGMD2I)

A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects with Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)

Limb Girdle Muscular Dystrophy trials by city

Other conditions